JAB-21822 (Not yet branded)
Other Medications
Description
JAB-21822 is a KRAS G12C inhibitor designed to target colorectal cancers harboring the specific KRAS G12C mutation. This targeted therapy represents a precision medicine approach for CRC patients whose tumors carry this particular oncogenic mutation. The drug is administered in combination with other agents including JAB-3312, standard chemotherapy with bevacizumab, or cetuximab depending on the treatment protocol.
Mechanism of Action
JAB-21822 works by selectively binding to and inhibiting the KRAS G12C mutant protein, which drives tumor growth and survival in approximately 3-5% of colorectal cancers. By targeting this specific mutant form of KRAS while sparing the wild-type protein, the drug aims to block downstream signaling pathways that promote cancer cell proliferation and survival.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.